With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active corporate investor in the European life science market in the last five years. The only other investor having reached the top … Read more
It is no surprise that the top 5 European investors have shown significantly higher activities than US investors in Europe from 2017 to 2021. Nevertheless, US investors such as SOSV, Epidarex Capital, OrbiMed, and RA … Read more
The capital raised in BioTech IPOs declined heavily in Europe and the US. For Q4’21 – Q1’22, the amount of raised capital declined by 73 percent compared to Q4’20 – Q1’21 (from EUR 5,941m to … Read more
Investors from China continue to show exceptional interest in young life science companies based in Europe. Investments made by Chinese VCs have significantly grown 17-fold over the last five years (from EUR 34m in 2017 … Read more
Venture capital markets continue to show high interest in companies with a focus on regenerative medicine from Europe and the US. Since 2017 the market has shown exceptional growth, as funding volumes increased threefold to … Read more
For the second time in a row, the Spanish healthcare VC market reaches a financing threshold of >EUR 300, doubling within only two years. From 2016 to 2018, the financing volumes totaled around EUR 150, … Read more
With a volume of roughly USD 33.0bn, the overall financing for US biotech companies in 2021 yet again surpassed the total funding of the previous year (USD 22.4bn). Compared to 2020, the funding volume increased … Read more
The program has become an important pillar in the European venture financing landscape to promote R&D projects of fast-growing companies from sectors such as ICT, deep tech, and life sciences. Starting in 2015, the EIB has supported … Read more
An increasing number of drugs of European origin have been in-licensed to Chinese biotechnology companies. Over the last five years, a steady increase in the number of yearly in-licensed assets from Europe can be observed. … Read more
Investment into US and European cannabis companies have been continuously increasing over the past years. Whereas 72 venture capital transactions were conducted in 2016, the number of transactions in 2021 (YTD) have increased by almost … Read more
